Article

Divalproex, lithium and suicide among Medicaid patients with bipolar disorder

Department of Psychiatry, CR-139, Oregon Health & Science University, Portland, Oregon 97239, United States.
Journal of Affective Disorders (Impact Factor: 3.71). 05/2008; 107(1-3):23-8. DOI: 10.1016/j.jad.2007.07.014
Source: PubMed

ABSTRACT Suicide completion and attempted suicide are major concerns for people with bipolar disorder. Studies in the private sector have suggested that lithium treatment may be superior to divalproex therapy with regard to minimizing suicidal behavior among individuals with bipolar disorder. However, few data are available regarding Medicaid patients diagnosed with bipolar disorder.
Subjects were 12,662 Oregon Medicaid patients diagnosed with bipolar disorder and treated with medication between 1998 and 2003. Outcomes measures were completed suicide and emergency department visits for suicide attempts (including non-fatal poisoning). Cox proportional hazards models were used to adjust for demographics, co-morbidity, and concurrent psychotropic medication use.
Divalproex was the most common mood stabilizer (used by 33% of subjects) followed by gabapentin (32%), lithium (25%), and carbamazepine (3%). There were 11 suicide deaths and 79 attempts. Adjusted hazard ratios (versus lithium users) for suicide attempts were 2.7 for divalproex users (p<0.001), 1.6 for gabapentin users (not significant) and 2.8 for carbamazepine users (not significant). For suicide deaths, the adjusted hazard ratios were 1.5 for divalproex users (not significant), 2.6 for gabapentin users (p<0.001), and not available for carbamazepine users.
It should be noted that subjects were not assigned at random to medication use, data on prior suicide attempts were not available, medication use was measured by automated pharmacy records, and duration of mood stabilizer utilization may have been brief.
Lithium may have a protective effect with regard to suicide attempts among Medicaid patients with bipolar disorder. It remains unclear whether or not lithium protects these patients against completed suicide.

0 Followers
 · 
59 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Repeated unavoidable stress induces in rats decreased reactivity to avoidable stressors and an anhedonia-like condition that are reverted by long-term antidepressant treatments and regarded as models of core symptoms of depression. Morphine-sensitized rats present resilience to stress-induced behavioral deficits and, if hyporeactivity to stress models a depressive symptom, stress resistance can be regarded as a manic symptom. This hypothesis is supported by the observation that long-term lithium administration reinstates sensitivity to stress in sensitized rats. The first aim of the study was to examine the effects of carbamazepine, a standard antimanic treatment, on the stress resilience of sensitized rats, to further characterize morphine sensitization as a model of manic symptom. Carbamazepine administration abolished stress resilience but did not interfere with the expression of sensitization. The second aim of the study was to assess whether repeated carbamazepine treatment affected the dopaminergic and behavioral responses to a natural reward, a palatable food (vanilla sugar, VS), in non food-deprived sensitized and control rats and compare these possible effects with those of repeated lithium administration. Control and sensitized rats showed increased extraneuronal dopamine levels in the nucleus accumbens shell after VS consumption and competence to acquire an instrumental VS-sustained appetitive behavior (VAB). Repeated carbamazepine treatment abolished the dopaminergic response to VS consumption and disrupted the competence to acquire VAB in control rats. Lithium-treated rats showed a dopaminergic response to VS and easily acquired the appetitive behavior. In sensitized rats, neither carbamazepine nor lithium administration interfered with the dopaminergic response to VS and the acquisition of VAB. In summary, the effect of carbamazepine on the stress resilience of sensitized rats further supported the hypothesis that morphine sensitization might model some symptoms of mania. Moreover, in control rats carbamazepine treatment elicited an anhedonia-like condition that clearly distinguished the effects of this drug from those of lithium.
    Pharmacology Biochemistry and Behavior 10/2011; 99(4):749-58. DOI:10.1016/j.pbb.2011.06.031 · 2.82 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Die Behandlung suizidaler Patienten gehört zu den anspruchvollsten Herausforderungen für alle Professionen im Gesundheitswesen. Aufgrund der enormen gesundheitspolitischen Bedeutung ist die Therapie suizidalen Verhaltens in den letzten Jahren mehr und mehr in den Mittelpunkt psychiatrischer Forschung gerückt und nimmt einen größeren Stellenwert in der Erarbeitung von Behandlungs- und Präventionsstrategien ein. Für Lithium als eine der ältesten in der Psychiatrie verwendeten psychotropen Substanzen wurde seit Anfang der 1990iger Jahre ein eigenständiger, im Vergleich zu anderen Psychopharmaka wahrscheinlich spezifischer antisuizidaler Effekt nachgewiesen. Trotz dieses Wissens und des heute ebenfalls in nationalen und internationalen Leitlinien dokumentierten Stellenwertes von Lithium in der Akut- und Erhaltungstherapie affektiver Störungen ist Lithium hinsichtlich seiner Verschreibungshäufigkeit im Vergleich zu anderen Psychopharmaka unterrepräsentiert. Der folgende Beitrag gibt eine chronologische Zusammenfassung aller wichtigen Studien, welche die antisuizidale Wirkung von Lithium untersucht haben, und diskutiert die daraus resultierenden therapeutischen Implikationen.
    Der Nervenarzt 03/2012; 84(3). DOI:10.1007/s00115-012-3542-5 · 0.86 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Relationships between antidepressant treatment and suicidality remain uncertain in major depressive disorder (MDD), and rarely evaluated in bipolar disorder (BPD). We evaluated changes in suicidality ratings (Hamilton Depression Rating Scale item-3) at the start and after 3.59 +/- 2.57 months of sustained antidepressant treatment in a systematically assessed clinical sample (n = 789) of 605 patients with MDD, 103 patients with BPD-II and 81 patients with BPD-I (based on DSM-IV; 68.1% women; aged 44.3 +/- 16.1 years), comparing suicidal vs. non-suicidal and recovered vs. unrecovered initially suicidal patients. Suicidal patients (103/789, 16.5%; BPD/MDD risk: 2.2) were more depressed and were ill longer. During treatment, 81.5% of suicidal patients became non-suicidal; 0.46% of 656 initially non-suicidal patients reported new suicidal thoughts, with no new attempts. Becoming non-suicidal was associated with greater depression severity and greater improvement. Suicidal ideation was prevalent in patients with depressed major affective disorder, but most of the initially suicidal patients became non-suicidal with antidepressant treatment, independent of diagnosis, treatment type or dose.
    Acta Psychiatrica Scandinavica 05/2008; 118(2):106-15. DOI:10.1111/j.1600-0447.2008.01178.x · 5.55 Impact Factor

Preview

Download
2 Downloads
Available from